Uppsala, Sweden, November 28, 2012 / B3C newswire / - Beactica, the leading Swedish fragment-based drug discovery company, today announced that it has added a project under its ongoing research services agreement with Janssen Research & Development, a division of Janssen Pharmaceutica NV. Under the research services agreement, Beactica will use its proprietary drug discovery platform Sprint™ to identify novel allosteric modulators targeting undisclosed central nervous system (CNS) proteins of therapeutic interest to Janssen. Financial terms of the agreement were not disclosed.
鈥淲e are pleased to extend our collaboration with Janssen and look forward to further supporting their efforts to discover innovative medicines鈥 said Beactica CEO, Dr Per Källblad. 鈥淭he extension of our relationship testifies to the ability of our Sprint™ platform to generate novel, high-quality medicinal chemistry starting points against challenging drug targets鈥.
Beactica initiated their first research services project with Janssen in early 2011.
About Beactica
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel and mechanistically defined therapeutics. The Company offers expertise and services in the area of surface plasmon resonance (SPR) biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using its proprietary Sprint™ platform. Founded in 2006 based on research carried out at Uppsala University and first-hand experience from the drug discovery industry, Beactica has established a robust reputation as the leader in SPR-based small molecule drug discovery. As well as providing services and building collaborations with external companies, Beactica is progressing its own drug discovery programmes. The Company has its headquarter in Uppsala, Sweden. For more information, please visit www.beactica.com.
Contact
Dr Per Källblad
Beactica CEO
+46 18 56 08 80
中文
